COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to methods for treating metabolic disorders, including diabetes by using a combination of an acylated glucagon analogue and an insulin analogue. The invention also features a kit that includes an acylated glucagon analogue and an insuline analogue.
25 Citations
116 Claims
-
1-4. -4. (canceled)
-
5. A method for preventing or reducing weight gain;
- promoting weight loss;
improving circulating glucose levels, glucose tolerance or circulating cholesterol levels;
lowering circulating LDL levels;
increasing HDL/LDL ratio;
or treating a condition caused or characterized by excess body weight, said method comprising administering to a mammalian subject a combination of compounds comprising;(a) a compound having the formula;
R1—
Z—
R2wherein R1 is H, C1-4 alkyl, acetyl, formyl, benzoyl, or trifluoroacetyl; R2 is OH or NH2; and Z is a peptide having the formula I;
His-X2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-X12-Tyr-Leu-Asp-X16-X17-Ala-Ala-X20-X21-Phe-Val-X24-Trp-Leu-X27-X28-Ala-X30 (SEQ ID NO;
6);
(I)wherein X2 is selected from Aib and Ser; X12 is selected from Lys, Arg, or Leu; X16 is selected from Arg and X; X17 is selected from Arg and X; X20 is selected from Arg, His, and X; X21 is selected from Asp and Glu; X24 is selected from Ala and X; X27 is selected from Leu and X; X28 is selected from Arg and X; X30 is X or is absent; wherein at least one of X16, X17, X20, X24, X27, X28, and X30 is X; and wherein each residue X is independently selected from the group consisting of Glu, Lys, Ser, Cys, Dbu, Dpr, and Orn; wherein the side chain of at least one residue X is conjugated to a lipophilic substituent having the formula; (i) Z1, wherein Z1 is a lipophilic moiety conjugated directly to the side chain of X;
or(ii) Z1Z2, wherein Z1 is a lipophilic moiety, Z2 is a spacer, and Z1 is conjugated to the side chain of X via Z2; and (b) an insulin analogue. - View Dependent Claims (6, 9, 12, 13, 14, 15, 16, 17, 18, 19, 23, 24, 26, 29, 35, 37, 39, 41, 42, 71, 93, 95, 99, 112, 113, 114)
- promoting weight loss;
-
7-8. -8. (canceled)
-
10-11. -11. (canceled)
-
20-22. -22. (canceled)
-
25. (canceled)
-
27-28. -28. (canceled)
-
30-34. -34. (canceled)
-
36. (canceled)
-
38. (canceled)
-
40. (canceled)
-
43-70. -70. (canceled)
-
72-92. -92. (canceled)
-
94. (canceled)
-
96-98. -98. (canceled)
-
100-108. -108. (canceled)
-
109. A kit comprising:
-
(a) a compound having the formula;
R1—
Z—
R2wherein R1 is H, C1-4 alkyl, acetyl, formyl, benzoyl, or trifluoroacetyl; R2 is OH or NH2, and Z is a peptide having the formula I;
His-X2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-X12-Tyr-Leu-Asp-X16-X17-Ala-Ala-X20-X21-Phe-Val-X24-Trp-Leu-X27-X28-Ala-X30;
(I)wherein X2 is selected from Aib and Ser; X12 is selected from Lys, Arg, or Leu; X16 is selected from Arg and X; X17 is selected from Arg and X; X20 is selected from Arg, His, and X; X21 is selected from Asp and Glu; X24 is selected from Ala and X; X27 is selected from Leu and X; X28 is selected from Arg and X; X30 is X or is absent; wherein at least one of X16, X17, X20, X24, X27, X28, and X30 is X; and wherein each residue X is independently selected from the group consisting of Glu, Lys, Ser, Cys, Dbu, Dpr, and Orn; wherein the side chain of at least one residue X is conjugated to a lipophilic substituent having the formula; (i) Z1, wherein Z1 is a lipophilic moiety conjugated directly to the side chain of X;
or(ii) Z1Z2, wherein Z1 is a lipophilic moiety, Z2 is a spacer, and Z1 is conjugated to the side chain of X via Z2; and (b) an insulin analogue. - View Dependent Claims (111)
-
-
110. (canceled)
-
115. A method for preventing or reducing weight gain;
- promoting weight loss;
improving circulating glucose levels, glucose tolerance or circulating cholesterol levels;
lowering circulating LDL levels;
increasing HDL/LDL ratio;
lowering circulating triacylglycerol levels, lowering circulating free fatty acids or treating a condition caused or characterized by excess body weight in a mammalian subject that is receiving an insulin analogue, said method comprising administering to said subject in an effective amount a compound having the formula;
R1—
Z—
R2wherein R1 is H, C1-4 alkyl, acetyl, formyl, benzoyl, or trifluoroacetyl; R2 is OH or NH2; and Z is a peptide having the formula I;
His-X2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-X12-Tyr-Leu-Asp-X16-X17-Ala-Ala-X20-X21-Phe-Val-X24-Trp-Leu-X27-X28-Ala-X30;
(I)wherein X2 is selected from Aib and Ser; X12 is selected from Lys, Arg, or Leu; X16 is selected from Arg and X; X17 is selected from Arg and X; X20 is selected from Arg, His, and X; X21 is selected from Asp and Glu; X24 is selected from Ala and X; X27 is selected from Leu and X; X28 is selected from Arg and X; X30 is X or is absent; wherein at least one of X16, X17, X20, X24, X27, X28, and X30 is X; and wherein each residue X is independently selected from the group consisting of Glu, Lys, Ser, Cys, Dbu, Dpr, and Orn; wherein the side chain of at least one residue X is conjugated to a lipophilic substituent having the formula; (i) Z1, wherein Z1 is a lipophilic moiety conjugated directly to the side chain of X;
or(ii) Z1Z2, wherein Z1 is a lipophilic moiety, Z2 is a spacer, and Z1 is conjugated to the side chain of X via Z2. - View Dependent Claims (116)
- promoting weight loss;
Specification